Clinical trial
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With…
NCT00028769 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00028769 |
|---|---|
| Title | S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel |
| Enrollment | 41 |
| Start date | Dec 1, 2001 |
| Primary completion | Jun 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 16, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: